Recent Finacing
Recent Raise
Symvivo develops the bacTRL plasmid DNA platform for oral and IV delivery enabling therapeutic protein expression, with room-temperature-stable, self-administered oral DNA vaccines and oncology, immunology, gene-replacement programs.
